Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make BiobettersReport as inadecuate




Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters - Download this document for free, or read online. Document in PDF available to download.

BioDrugs

, Volume 29, Issue 4, pp 215–239

First Online: 16 July 2015

Abstract

The purpose of making a -biobetter- biologic is to improve on the salient characteristics of a known biologic for which there is, minimally, clinical proof of concept or, maximally, marketed product data. There already are several examples in which second-generation or biobetter biologics have been generated by improving the pharmacokinetic properties of an innovative drug, including Neulasta a PEGylated, longer-half-life version of Neupogen filgrastim and Aranesp a longer-half-life version of Epogen epoetin-α. This review describes the use of protein fusion technologies such as Fc fusion proteins, fusion to human serum albumin, fusion to carboxy-terminal peptide, and other polypeptide fusion approaches to make biobetter drugs with more desirable pharmacokinetic profiles.

Download fulltext PDF



Author: William R. Strohl

Source: https://link.springer.com/article/10.1007/s40259-015-0133-6







Related documents